Ask Dr. Miller
When Ladies First providers, as well as health care practitioners around the nation, come across breast and cervical cancer screening, diagnostic and treatment issues they cannot answer, Dr. Jacqueline W. Miller provides answers through her forum, Ask Dr. Miller.
Dr. Miller is a board-certified general surgeon and a Commander with the U.S. Public Health Service. She did her undergraduate education at Spelman College in Atlanta, GA and earned her medical degree from Washington University School of Medicine in St. Louis, MO. She has practiced General Surgery for eight years in Atlanta with a special interest in breast cancer. Since then she has remained at the CDC as Medical Officer and is currently the Medical Director for CDC's National Breast and Cervical Cancer Early Detection Program in the Division of Cancer Prevention and Control.
If you have any questions about the Ladies First program, you should first call our offices at 1-800-508-2222.
Reprinted below are questions and responses from her forum. Should you wish to email her directly, her address is email@example.com
Dr. Miller has authored or co-authored over 60 publications and mentors fellows training in epidemiology.
Some of the most recent articles Dr. Miller has first-authored include—
- 2015 Breast and cervical cancers diagnosed and stage at diagnosis among women served through the National Breast and Cervical Cancer Early Detection Program.
- 2014 From cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection Program.
- 2014 Public health national approach to reducing breast and cervical cancer disparities.
- 2014 Physicians’ beliefs about effectiveness of cancer screening tests: a national survey of family physicians, general internists, and obstetrician-gynecologists.
- 2012 Breast MRI use uncommon among U.S. women.
- 2012 Breast cancer screening among adult women—Behavioral Risk Factor Surveillance System, United States, 2010.
- 2009 Mammography use from 2000 to 2006: state-level trends with corresponding breast cancer incidence rates.